Since CD274/PD-L1 was upregulated in DEV cells after coculture and in LP-DLBCL biopsies, checkpoint inhibitors could prevent the exhaustion of the relative high number of CD8-positive T cells in the microenvironment [41] and patients with LP-DLBCL could particularly benefit from such therapies. The gene discussed is CD8A; the disease is diffuse large B-cell lymphoma.